anti-CD3/anti-Globo H bispecific T-cell engager (Development Center for Biotechnology)

N/A

Report date: 2026/03/19 16:53:49

Base Information

Drug Nameanti-CD3/anti-Globo H bispecific T-cell engager (Development Center for Biotechnology)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > T cell engagers

Mechanisms of ActionT cell surface glycoprotein CD3 modulators

TargetsT cell surface glycoprotein CD3

Therapy Area/IndicationsOvarian NeoplasmsPancreatic NeoplasmsBreast Neoplasms +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryTaiwan

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesDevelopment Center for Biotechnology

China Registration ClassN/A

Develop Information

Active CompaniesDevelopment Center for Biotechnology

Inactive CompaniesN/A

Active IndicationsOvarian NeoplasmsPancreatic NeoplasmsBreast Neoplasms +[4]

Inactive IndicationsN/A

Other Information

ATC CodeN/A